- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- April 2025
- 200 Pages
Global
From €6963EUR$7,950USD£6,043GBP
- Report
- June 2025
- 400 Pages
Global
From €4334EUR$4,949USD£3,762GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3284EUR$3,750USD£2,851GBP
- Report
- July 2024
- 231 Pages
Global
From €6963EUR$7,950USD£6,043GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2409EUR$2,750USD£2,090GBP
Xeljanz XR is a drug used to treat immune disorders, such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It is a Janus kinase (JAK) inhibitor, which works by blocking certain proteins that are involved in the body's inflammatory response. Xeljanz XR is taken orally, usually once daily. It is available in both immediate-release and extended-release formulations.
Xeljanz XR is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2012. It is one of several drugs used to treat immune disorders, and is often used in combination with other medications.
The Xeljanz XR market is highly competitive, with several major pharmaceutical companies offering the drug. These include Pfizer, AbbVie, and Janssen Pharmaceuticals. Other companies, such as Amgen and Celgene, also offer similar drugs. Show Less Read more
